Clinical Scorecard: Trends in Tuberculosis Notifications and Treatment Results in Bangladesh: Insights from National TB Program Data (2019–2021)
At a Glance
Category
Detail
Condition
Tuberculosis (TB), including pulmonary and extrapulmonary forms
Key Mechanisms
Mycobacterium tuberculosis infection diagnosed via microbiological and clinical criteria; treatment outcomes monitored through national surveillance
Target Population
All patients treated for TB in Bangladesh, including children and adults
Care Setting
National Tuberculosis Program (NTP) treatment centers across Bangladesh, supported by WHO and partners
Key Highlights
Bangladesh is among the 30 high TB burden countries, contributing 3.4% of global cases with notable pediatric diagnostic and mortality challenges.
The National Tuberculosis Program achieved treatment success rates exceeding 90% pre-pandemic, with COVID-19 causing disruptions in TB services and case detection.
The e-TB Manager system provides comprehensive, standardized surveillance data enabling analysis of notification trends, treatment outcomes, and risk stratification.
Guideline-Based Recommendations
Diagnosis
Use microbiological confirmation via culture, nucleic acid amplification tests (e.g., GeneXpert MTB/RIF), or acid-fast bacilli identification.
Diagnose pulmonary TB based on chest X-ray and sputum analysis; diagnose extrapulmonary TB using radiographic, histopathological, or clinical evidence.
Classify cases according to WHO and national standards to ensure consistency and epidemiological relevance.
Management
Treat all confirmed TB cases according to National Tuberculosis Treatment Guidelines aligned with WHO recommendations.
Provide timely and quality treatment for both drug-sensitive and drug-resistant TB cases.
Strengthen programmatic support at the Upazila level and coordinate with WHO for technical and logistical assistance.
Monitoring & Follow-up
Systematically collect and validate treatment outcome data through the e-TB Manager platform.
Use treatment outcome data as feedback for resource allocation, quality improvement, and targeted interventions.
Monitor age-specific outcomes, especially in children under 5 years, to address higher mortality risks.
Risks
Recognize increased mortality risk in children under 5 years and diagnostic delays in pediatric populations.
Address disruptions caused by the COVID-19 pandemic impacting case detection and treatment adherence.
Identify and manage drug-resistant TB and comorbidities to prevent unsuccessful treatment outcomes.
Patient & Prescribing Data
All notified TB patients in Bangladesh between 2019 and 2021, including children and adults
Treatment success rates exceeded 90% pre-pandemic; COVID-19 caused declines in case detection and treatment adherence, highlighting the need for sustained programmatic support and monitoring.
Clinical Best Practices
Adhere strictly to WHO and national guidelines for TB diagnosis and treatment classification.
Utilize integrated electronic surveillance systems like e-TB Manager for comprehensive data capture and validation.
Focus on early detection and management of drug-resistant TB and high-risk subpopulations, including children under 5 years.
Implement targeted interventions to mitigate COVID-19 related disruptions and sustain TB control progress.
Use treatment outcome data to inform continuous quality improvement and resource allocation.
by Mohammad Julhas Sujan, Afzalur Rahman, Abu Taleb, Ahmadul Hasan Khan, Shanjida Rahman Sultana, Mohammad Ali Moni, Hasan Mahmud Reza, Md Hasinur Rahman Khan, Ahmed Hossain
